Tags : OxThera

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary Hyperoxaluria 2.Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program Published: Aug 22, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology […]Read More

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan

Shots: The approval of the Pediatric Investigational Plan (PIP) is based on PDCO’s positive opinion for Oxabact (Oxalobacter formigenes) to treat pediatric patients with primary hyperoxaluria Oxabact is currently evaluated in an ongoing P-III PBO controlled clinical study across sites the US and Europe, monitoring the change in plasma oxalate and estimated glomerular filtration rate […]Read More